Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05028829 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk
A Phase 2 study of Cirrhosis and Liver Fibroses, sponsored by Raymond Chung.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT05028829: Recruiting Phase 2 study of Cirrhosis and Liver Fibroses, sponsored by Raymond Chung.
NCT05028829 is a Phase 2 study of Cirrhosis and Liver Fibroses that is actively recruiting participants, run by Raymond Chung. The registered enrollment target is 60 participants, below the 90,408-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05028829, a Phase 2 study of Cirrhosis and Liver Fibroses, is actively recruiting participants, sponsored by Raymond Chung.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
Prospective randomized, multi-center, double blind placebo-controlled trial to assess the chemopreventive impact of atorvastatin (20 mg oral) vs placebo in up to 60 adults with advanced fibrosis at high risk of developing HCC.
Primary Outcome
The primary objective (primary endpoint) of this study is to determine the effect of atorvastatin compared with placebo on HCC risk level measured by change in serum-based prognostic liver secretome signature (PLSec) score (delta-PLSec). High-risk for HCC is indicated by a PLSec score of 3 or greater. Low-risk for HCC is indicated by a PLSec score below 3.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Atorvastatin 20mg
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-05-10 |
| Est. Completion | 2031-03-01 |
| Phase | Phase 2 |
What NCT05028829 shows while recruiting
NCT05028829 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 90,408-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Cirrhosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05028829 reports a single indexed study location in Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT05028829 about?
NCT05028829 is a clinical study titled "Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk". Prospective randomized, multi-center, double blind placebo-controlled trial to assess the chemopreventive impact of atorvastatin (20 mg oral) vs placebo in up to 60 adults with advanced fibrosis at high risk of developing HCC.
What is the current status of trial NCT05028829?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-05-10. Estimated completion is 2031-03-01.
What conditions does trial NCT05028829 study?
This clinical trial studies the following conditions: Cirrhosis, Liver Fibroses.
What interventions are being tested in trial NCT05028829?
The interventions under investigation include: Placebo (DRUG), Atorvastatin 20mg (DRUG).
Who is sponsoring clinical trial NCT05028829?
This trial is sponsored by Raymond Chung, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05028829 being conducted?
This trial has 2 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05028829's enrollment target sits among peer trials
60 23rd of 53 higher than 30 of 53 other Cirrhosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cirrhosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
RECRUITING · Phase 2
-
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
RECRUITING · Phase 2
-
Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis
RECRUITING · Phase 2
-
Empagliflozin in Patients With Cirrhosis and Ascites
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI